First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
There has been no loss or injury to human life
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
The company is assessing the situation and simultaneously undertaking all the requisite action
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Subscribe To Our Newsletter & Stay Updated
